Sanara MedTech Inc. (SMTI): Submission of Matters to a Vote of Security Holders

Sanara MedTech (SMTI) seeks shareholder approval for a merger with MiMedx. Shareholders will receive $33.00 in cash plus 0.4735 MiMedx shares per Sanara share, valued at roughly $35 per share. The merger requires shareholder approval at a September 30 meeting, with key shareholders already committing their votes in favor.

Sanara MedTech (SMTI) agreed to be acquired by MiMedx Group. The deal, announced on July 29, 2026, is expected to close by year-end, subject to regulatory approvals and other conditions. Both companies will operate independently until the transaction is finalized.

Sanara MedTech (NASDAQ: SMTI) reported Q2 EPS of $(0.05), missing the $0.02 consensus, and sales of $28.137 million, up 8.93% YoY but below the $28.950 million estimate. The article also says Kahn Swick & Foti opened an investigation into SMTI’s proposed acquisition by MiMedx (NASDAQ: MDXG), valuing the deal at about $350 million ($35.00 per SMTI share).

Sanara MedTech Inc. reported Q2 2026 revenue of $28.14M, up 9.1% year over year from $25.80M. Net loss attributable to shareholders was $0.45M, versus $2.01M a year earlier, and diluted EPS was $(0.05) versus $(0.23). The company cited product sales growth and updates including a Vizient contract and a merger agreement with MiMedx, per its 10-Q.

MiMedx Group (Nasdaq: MDXG) filed an 8-K/A amending its July 29, 2026 report to correct Sanara and MiMedx termination fee amounts. It also describes a merger where Sanara shareholders receive $33.00 cash per share plus 0.4735 shares of MiMedx common stock. MiMedx will issue stock and file an S-4.

Sanara MedTech Inc. (SMTI) filed Amendment No. 1 to its Form 8-K to correct Item 1.01 termination-fee amounts: the fee was misstated as $22,540,785.00 instead of $9,660,336.00, and vice versa for MiMedx Group, Inc. The merger terms remain unchanged. Under the merger, SMTI shareholders receive $33.00 cash and 0.4735 shares of MiMedx common stock per share.